Phenotypes associated with this allele

• Allele Symbol: Mir148a^tm2942.1Arte
• Allele Name: targeted mutation 2942.1, TaconicArtemis
• Allele ID: MGI:6720859
• Summary: 2 genotypes

Jump to	Allelic Composition	Genetic Background	Genotype ID
cn1	Mir148a^tm2942.1Arte/Mir148a^tm2942.1Arte Cd19^tm1(cre)Cgn/Cd19^+	involves: 129P2/OlaHsd * C57BL/6	MGI:6731079
cn2	Mir148a^tm2942.1Arte/Mir148a^tm2942.1Arte Gt(ROSA)26Sor^tm9(cre/ESR1)Arte/Gt(ROSA)26Sor^+	involves: C57BL/6 * C57BL/6NTac	MGI:6731094

Genotype
MGI:6731079

cn1

• Allelic Composition: Mir148a^tm2942.1Arte/Mir148a^tm2942.1Arte; Cd19^tm1(cre)Cgn/Cd19⁺
• Genetic Background: involves: 129P2/OlaHsd * C57BL/6

• ♀: phenotype observed in females
• ♂: phenotype observed in males
• N: normal phenotype

immune system

decreased plasma cell number ( J:307366 )

• a reduction between 30 and 50% in IgA-secreting cells in spleen and bone marrow

• a reduction between 30 and 50% in IgG-secreting cells in the bone marrow

• marker analysis shows a 50% reduction of splenic CD138/Taci+ plasmablast/plasma cell numbers; this decrease is attributed to the approximate 60% decrease in the late CD19-negative mature plasma cell subset

• the number of late CD19-negative P3-plasma cells is reduced in the bone marrow by approximately 50%, but only in the Taci+ plasma cell subset with a high abundance of surface CD138

increased memory B cell number ( J:307366 )

• 42 days after NP-KLH immunization, mice show a trend of increased numbers of NP-specific memory B cells (CD38-sIgG+) cells in the spleen and bone marrow

• numbers of pro-B cells, pre-B cells, immature B cells, and recirculating mature B cells in the bone marrow are unaltered in non-immunized mice

abnormal plasmablast number ( J:307366 )

• differentiation of germinal center B cells into plasmablasts is impaired resulting in a decrease in numbers of newly formed plasmablasts after immunization with NP-KLH

• however, the number of germinal center B cells is not altered

decreased IgA level ( J:307366 )

• serum IgA levels are reduced by roughly 50% in non-immunized mice

decreased IgG level ( J:307366 )

• serum IgG levels are reduced by roughly 50% in non-immunized mice

• mice immunized with the thymus-dependent model antigen TNP-KLH show reduced TNP-specific IgG titers

decreased IgM level ( J:307366 )

• serum IgM levels are reduced by roughly 50% in non-immunized mice

impaired humoral immune response ( J:307366 )

• mice show reduced antigen-specific antibody responses

• TNP-KLH-immunized mice show a 50% reduction in the number of TNP-specific IgG- or IgM-secreting cells in the spleen and bone marrow 70 days after primary immunization

• TNP-KLH-immunized mice show a reduction in the CD138/Taci+ plasmablast/plasma cell population in the spleen and bone marrow, indicating fewer mature P3-plasma cells

• however, the number of P1-plasmablasts and P2-plasma cells in the spleen and bone marrow are not reduced in TNP-KLH-immunized mice

• mice show lower numbers of P1-plasmablasts in the blood 14 days after primary immunization with TNP-KLH

• TNP-KLH immunized mice show a more pronounced shift to CD19+ cells in CD138/Taci+ populations under homeostatic conditions

• the number of CD138^low early P2-plasma cells in the bone marrow is elevated in TNP-KLH immunized mice

hematopoietic system

decreased plasma cell number ( J:307366 )

• a reduction between 30 and 50% in IgA-secreting cells in spleen and bone marrow

• a reduction between 30 and 50% in IgG-secreting cells in the bone marrow

• marker analysis shows a 50% reduction of splenic CD138/Taci+ plasmablast/plasma cell numbers; this decrease is attributed to the approximate 60% decrease in the late CD19-negative mature plasma cell subset

• the number of late CD19-negative P3-plasma cells is reduced in the bone marrow by approximately 50%, but only in the Taci+ plasma cell subset with a high abundance of surface CD138

increased memory B cell number ( J:307366 )

• 42 days after NP-KLH immunization, mice show a trend of increased numbers of NP-specific memory B cells (CD38-sIgG+) cells in the spleen and bone marrow

• numbers of pro-B cells, pre-B cells, immature B cells, and recirculating mature B cells in the bone marrow are unaltered in non-immunized mice

abnormal plasmablast number ( J:307366 )

• differentiation of germinal center B cells into plasmablasts is impaired resulting in a decrease in numbers of newly formed plasmablasts after immunization with NP-KLH

• however, the number of germinal center B cells is not altered

decreased IgA level ( J:307366 )

• serum IgA levels are reduced by roughly 50% in non-immunized mice

decreased IgG level ( J:307366 )

• serum IgG levels are reduced by roughly 50% in non-immunized mice

• mice immunized with the thymus-dependent model antigen TNP-KLH show reduced TNP-specific IgG titers

decreased IgM level ( J:307366 )

• serum IgM levels are reduced by roughly 50% in non-immunized mice

Genotype
MGI:6731094

cn2

• Allelic Composition: Mir148a^tm2942.1Arte/Mir148a^tm2942.1Arte; Gt(ROSA)26Sor^{tm9(cre/ESR1)Arte}/Gt(ROSA)26Sor⁺
• Genetic Background: involves: C57BL/6 * C57BL/6NTac

hematopoietic system

decreased plasma cell number ( J:307366 )

• reduction in the number of mature resting plasma cells in the bone marrow following immunization with TNP-KLH and treatment with tamoxifen

increased plasma cell number ( J:307366 )

• the number of P3-plasma cells in the blood in elevated in TNP-KLH immunized and boosted mice treated with tamoxifen

abnormal plasmablast number ( J:307366 )

• the number of P1-plasmablasts is diminished in the spleen in TNP-KLH immunized and boosted mice treated with tamoxifen

abnormal B cell physiology ( J:307366 )

• reduction in EdU+ mature P3-plasma cells in the bone marrow of TNP-KLH immunized and tamoxifen treated mice indicating reduced mature plasma turnover

• however, the EdU+ P2-plasma cell subset is unchanged

immune system

decreased plasma cell number ( J:307366 )

• reduction in the number of mature resting plasma cells in the bone marrow following immunization with TNP-KLH and treatment with tamoxifen

increased plasma cell number ( J:307366 )

• the number of P3-plasma cells in the blood in elevated in TNP-KLH immunized and boosted mice treated with tamoxifen

abnormal plasmablast number ( J:307366 )

• the number of P1-plasmablasts is diminished in the spleen in TNP-KLH immunized and boosted mice treated with tamoxifen

abnormal B cell physiology ( J:307366 )

• reduction in EdU+ mature P3-plasma cells in the bone marrow of TNP-KLH immunized and tamoxifen treated mice indicating reduced mature plasma turnover

• however, the EdU+ P2-plasma cell subset is unchanged

impaired humoral immune response ( J:307366 )

• mice immunized and boosted with TNP-KLH and treated with tamoxifen exhibit a reduction in the CD138/Taci+ plasmablast/plasma cell population, notably the CD19-negative mature resting P3-plasma cells in the spleen and bone marrow

• mice immunized and boosted with TNP-KLH and treated with tamoxifen show a decrease in total number of antibody secreting cells in the bone marrow

• however, the numbers of NTP-specific antibody secreting in the spleen and bone marrow remain unchanged after tamoxifen treatment